Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer

Molecular Imaging and Theragnostics of Thyroid Cancers

Radioactive Iodine Refractory Differentiated Thyroid Cancer Targeted Therapy

Next-Generation Molecular Imaging of Thyroid Cancer

Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead

The Fundamental Role of Radioiodine in the Management of Thyroid Cancer

Radioiodine-refractory Differentiated Thyroid Cancer: Molecular Mechanisms and Therapeutic Strategies for Radioiodine Resistance.

Systemic treatments for radioiodine-refractory thyroid cancers

Advances in the Development of Positron Emission Tomography Tracers for Improved Detection of Differentiated Thyroid Cancer

State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer

Appraisal of Radioiodine Refractory Thyroid Cancer: Advances and Challenges

Molecular Image-Guided Theranostic and Personalized Medicine 2013

Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice

Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review

Diagnosis and Targeted Therapy of Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Can 99 Tc m -3PRGD 2 (α ν β 3 ) and 18 F-FDG dual-tracer molecular imaging change the therapeutic strategy for progressive refractory differentiated thyroid cancer: Case report

Progress in Diagnosis and Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Carcinomas

Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging

Updated Review of Nuclear Molecular Imaging of Thyroid Cancers.

[Progress in diagnosis and treatment of radioactive iodine-refractory differentiated thyroid carcinoma].